Home⇛Science Asia Review⇛vol. 10 no. 1 (2024)

Remission and Response Rates in Pharmacogenetic-Guided Antidepressant Treatment of Major Depressive Disorder (MDD) Compared to Conventional Treatment: A Systematic Review and Meta- Analysis

Norfaizier Jumdail

Discipline: Healthcare Sciences

 

Abstract:

Major Depressive Disorder (MDD) is a prevalent mental health condition that significantly impacts individuals and society. The effectiveness of antidepressant treatment varies among patients, leading to a growing interest in personalized medicine approaches. This study aimed to investigate the response and remission rates of pharmacogenetic-guided antidepressant treatment compared to conventional treatment in patients with MDD. Through a comprehensive systematic review and meta-analysis, this research revealed promising findings. This study adhered to the PRISMA guidelines, ensuring transparency and quality in reporting. The PICO framework provided a structured approach to formulating research questions, identifying relevant studies, and analyzing outcomes. The analysis demonstrated that pharmacogenetic-guided treatment could enhance remission and response rates in individuals with MDD. The meta-analysis revealed significantly higher remission (RR: 1.17 with 95% CI: 0.98 to 1.38) and response (RR: 1.46 with a 95% CI ranging from 1.05 to 2.01) rates in patients undergoing pharmacogenetic-guided treatment, as evidenced by consistently favourable risk ratios across multiple studies, suggesting a clear advantage over conventional treatment. However, further research is needed to explore the factors influencing treatment response and ascertain pharmacogeneticguided treatment's overall effectiveness in MDD. These findings emphasize the potential of pharmacogenetics as a valuable tool in personalized medicine and provide valuable insights for clinicians and researchers seeking to optimize treatment strategies for individuals with Major Depressive Disorder



References:

  1. Al-Harbi, K. S. (2012). Treatment-resistant depression: Therapeutic trends, challenges, and future directions. *Patient Preference and Adherence, 6*, 369–388. https://doi.org/10.2147/PPA.S29716
  2. Anderson, H. D., Thant, T. M., Kao, D. P., Crooks, K. R., Mendola, N. D., & Aquilante, C. L. (2022). Pharmacogenetic testing among patients with depression in a U.S. managed care population.
  3. Bandelow, B., Michaelis, S., & Wedekind, D. (2017). Treatment of anxiety disorders. *Dialogues in Clinical Neuroscience, 19*(2), 93–107. https://doi.org/10.31887/DCNS.2017.19.2/bbandelow
  4. Bains, N., & Abdijadid, S. (2023). Major depressive disorder. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK559078/
  5. Bradley, P., Shiekh, M., Mehra, V., Vrbicky, K., Layle, S., Olsong, M. C., Maciel, A., Cullors, A., Garces, J. A., & Lukowiak, A. A. (2018). Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility.
  6. Boland, J. R., Duffy, B., & Myer, N. M. (2018). Clinical utility of pharmacogenetics-guided treatment of depression and anxiety.
  7. Bousman, C. A., Arandjelovic, K., Mancuso, S. G., Eyre, H. A., & Dunlop, B. W. (2019). Pharmacogenetic tests and depressive symptom remission: A meta-analysis of randomized controlled trials. *Pharmacogenomics, 20*(1), 37–47. https://doi.org/10.2217/pgs-2018-0142
  8. Brigitta, B. (2002). Pathophysiology of depression and mechanisms of treatment. *Dialogues in Clinical Neuroscience, 4*(1), 7–20. https://doi.org/10.31887/DCNS.2002.4.1/bbondy
  9. Chang, D. D., Eyreeuro, H. A., Abbott, R., Coudreaut, M., Baune, B. T., Shaman, J. A., Lavretsky, H., Lenze, E. J., Merrill, D. A., Singh, A. B., Mulsant, B. H., Reynolds, C. F., 3rd, Müller, D. J., & Bousman, C. (2018). Pharmacogenetic guidelines and decision support tools for depression treatment: Application to late-life. *Pharmacogenomics*.
  10. Fabbri, C., Porcelli, S., & Serretti, A. (2014). From pharmacogenetics to pharmacogenomics: The way toward the personalization of antidepressant treatment. *Canadian Journal of Psychiatry, 59*(2), 62–75. https://doi.org/10.1177/070674371405900202
  11. Greden, J. F., Parikh, S. V., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Mondimore, F. M., Shelton, R. C., Macaluso, M., Li, J., Brown, K., Gilbert, A., Burns, L., Jablonski, M. R., & Dechairo, B. (2019). Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. *Journal of Psychiatric Research, 111*, 59–67. https://doi.org/10.1016/j.jpsychires.2019.01.003
  12. Han, C., Wang, S.-M., Bahk, W.-M., Lee, S.-J., Patkar, A. A., Masand, P. S., Mandelli, L., Pae, C.-U., & Serretti, A. (2018). A pharmacogenomic-based antidepressant treatment for patients with major depressive disorder: Results from an 8-week, randomized, single-blinded clinical trial. https://doi.org/10.9758/cpn.2018.16.4.469
  13. Hillhouse, T. M., & Porter, J. H. (2015). A brief history of the development of antidepressant drugs: From monoamines to glutamate. *Experimental and Clinical Psychopharmacology, 23*(1), 1–21. https://doi.org/10.1037/a0038550
  14. Kane, M. (2021). CYP2D6 overview: Allele and phenotype frequencies. In V. M. Pratt, S. A. Scott, & M. Pirmohamed (Eds.), *Medical Genetics Summaries*. National Center for Biotechnology Information. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK574601/
  15. Kessler, R. C., Berglund, P., & Demler, O. (2003). The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R).
  16. Licinio, J., & Wong, M. L. (2011). Pharmacogenomics of antidepressant treatment effects. *Dialogues in Clinical Neuroscience, 13*(1), 63–71. https://doi.org/10.31887/DCNS.2011.13.1/jlicinio
  17. Oslin, D. W., Lynch, K. G., Shih, M. C., Ingram, E. P., Wray, L. O., Chapman, S. R., Kranzler, H. R., Gelernter, J., Pyne, J. M., Stone, A., & DuVall, S. L. (2022). Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: The PRIME Care randomized clinical trial. *JAMA, 328*(2), 151–161. https://doi.org/10.1001/jama.2022.9805
  18. Papastergiou, J., Quilty, L. C., Li, W., Thiruchselvam, T., Jain, E., Gove, P., Mandlsohn, L., van den Bemt, B., & Pojskic, N. (2021). Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial.
  19. Pérez, V., Salavert, A., Espadaler, J., & others. (2017). Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: Results of a randomized, double-blind clinical trial. *BMC Psychiatry, 17*, 250. https://doi.org/10.1186/s12888-017-1412-1
  20. Perlis, R. H., Dowd, D., Fava, M., Lencz, T., & Krause, D. S. (2020). Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder. *Depression and Anxiety, 37*(6), 530–539. https://doi.org/10.1002/da.23029
  21. Sheffler, Z. M., Patel, P., & Abdijadid, S. (2023). Antidepressants. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK538182/
  22. Singh, A. B. (2015). Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report.
  23. Stäuble, C. K., Lampert, M. L., Mikoteit, T., Hatzinger, M., Hersberger, K. E., & Meyer zu Schwabedissen, H. E. (2021). Pharmacogenetic-guided antidepressant selection as an opportunity for interprofessional collaboration: A case report. *Life, 11*(7), 673. https://doi.org/10.3390/life11070673
  24. Thase, M. E., Parikh, S. V., Rothschild, A. J., et al. (2019). Impact of pharmacogenomics on clinical outcomes for patients taking medications with gene-drug interactions in a randomized controlled trial. *Journal of Clinical Psychiatry, 80*(6), 19m12910.
  25. Tiwari, A. K., Zai, C. C., Altar, C. A., Tanner, J.-A., & Davies, P. E. (2022). Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial. https://doi.org/10.1038/s41398-022-01847-8
  26. Whyte, J. (2014). Contributions of treatment theory and enablement theory to rehabilitation research and practice. *Archives of Physical Medicine and Rehabilitation, 95*(1 Suppl), S17–S 23. https://doi.org/10.1016/j.apmr.2013.02.029
  27. Winner, J. G. (2013). A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder.

Tools


Copyright © 2025  KITE Digital Educational Solutions |  Exclusively distributed by CE-Logic